2 weeks Ago By ABMN Staff
William Blair reaffirmed their outperform rating on shares of Exagen ( NASDAQ:XGN – Free Report ) in a report published on Wednesday morning, RTT News reports. William Blair also issued estimates for Exagen’s Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.
16) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.
55) EPS and FY2026 earnings at ($0.23) EPS. XGN has been the topic of several other reports.
Canaccord Genuity Group boosted their target price on Exagen from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd.
Cantor Fitzgerald reiterated an “overweight” rating and set a $8.00 price target on shares of Exagen in a research note on Monday, January 13th. Read Our Latest Analysis on Exagen Exagen Trading Up 6.
3 % Hedge Funds Weigh In On Exagen Several institutional investors and hedge funds have recently modified their holdings of the stock. Toronto Dominion Bank acquired a new position in shares of Exagen in the 4th quarter valued at about $3,655,000. Stonepine Capital Management LLC lifted its holdings in shares of Exagen by 49.
0% in the 3rd quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company’s stock valued at $1,651,000 after buying an additional 175,701 shares during the period. Driehaus Capital Management LLC acquired a new position in shares of Exagen in the 4th quarter valued at about $1,716,000.
Kennedy Capital Management LLC lifted its holdings in shares of Exagen by 8.8% in the 4th quarter. Kennedy Capital Management LLC now owns 184,473 shares of the company’s stock valued at $756,000 after buying an additional 14,920 shares during the period.
Finally, Geode Capital Management LLC lifted its holdings in shares of Exagen by 11.9% in the 4th quarter. Geode Capital Management LLC now owns 98,057 shares of the company’s stock valued at $402,000 after buying an additional 10,442 shares during the period.
Institutional investors and hedge funds own 75.25% of the company’s stock. About Exagen ( Get Free Report ) Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States.
The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Further Reading Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter .
.
